2021
Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series
Muzumdar S, Leonardi C, Strober B. Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series. Journal Of Psoriasis And Psoriatic Arthritis 2021, 6: 93-98. DOI: 10.1177/2475530321995516.Peer-Reviewed Original ResearchPalmoplantar psoriasisCase seriesEfficacy of tofacitinibRecalcitrant palmoplantar psoriasisSubtypes of psoriasisPsoriasis refractorySystemic therapyPatients' qualityNew medicationsEffective therapyPsoriasis phenotypesSpecific cytokinesPsoriasisTofacitinibTherapyTreatmentMedicationsPatientsCytokinesSubtypes
2020
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies
Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rahimi RS, Rupani RN, Siegel M, Stoff B, Strober BE, Tapper EB, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. Journal Of The American Academy Of Dermatology 2020, 82: 1445-1486. PMID: 32119894, DOI: 10.1016/j.jaad.2020.02.044.Peer-Reviewed Original ResearchConceptsDermatology–National Psoriasis Foundation guidelinesManagement of psoriasisTreatment of psoriasisChronic inflammatory diseaseFumaric acid estersMultiple organ systemsJoint American AcademyNonbiologic medicationsNonbiologic therapiesInflammatory diseasesFoundation guidelinesNew therapiesAmerican AcademyOrgan systemsMedicationsPsoriasisTherapyTreatmentDiseaseGuidelinesTofacitinibAcitretinPatientsApremilastPrescribers
2016
New Therapies for Psoriasis.
Strober B. New Therapies for Psoriasis. Seminars In Cutaneous Medicine And Surgery 2016, 35: s71-s73. PMID: 29850660, DOI: 10.12788/j.sder.2016.020.Peer-Reviewed Original Research
2015
Current and Future Oral Systemic Therapies for Psoriasis
Kelly J, Foley P, Strober B. Current and Future Oral Systemic Therapies for Psoriasis. Dermatologic Clinics 2015, 33: 91-109. PMID: 25412786, DOI: 10.1016/j.det.2014.09.008.Peer-Reviewed Original ResearchMeSH KeywordsAcitretinAnti-Inflammatory Agents, Non-SteroidalAntimetabolitesCyclosporineFumaratesHumansHydroxyureaImmunosuppressive AgentsIsoxazolesKeratolytic AgentsLeflunomideMethotrexateMycophenolic AcidPiperidinesProtein Kinase InhibitorsPsoriasisPyrimidinesPyrrolesSulfasalazineThalidomideThioguanine
2014
Understanding therapeutic pathways and comorbidities in psoriasis.
Gordon K, Strober B. Understanding therapeutic pathways and comorbidities in psoriasis. Seminars In Cutaneous Medicine And Surgery 2014, 33: s20-3. PMID: 24979540, DOI: 10.12788/j.sder.0067.Peer-Reviewed Original ResearchConceptsImmunologic pathwaysQuality of lifeJoint symptomsBiologic medicationsPathophysiologic pathwaysSystemic diseaseTherapeutic armamentariumInflammatory diseasesTherapeutic pathwaysPsoriasisKeratinocyte proliferationMedicationsHealth risksDiseasePathwayComorbiditiesMorbiditySymptomsArmamentariumMortalityMethotrexate and cyclosporine in psoriasis revisited.
Strober B. Methotrexate and cyclosporine in psoriasis revisited. Seminars In Cutaneous Medicine And Surgery 2014, 33: s27-30. PMID: 24979542, DOI: 10.12788/j.sder.0066.Peer-Reviewed Original Research
2010
The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics.
Levine D, Strober B. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics. Seminars In Cutaneous Medicine And Surgery 2010, 29: 28-34. PMID: 20430305, DOI: 10.1016/j.sder.2010.02.003.Peer-Reviewed Original ResearchConceptsSevere psoriasisUS FoodDrug AdministrationTumor necrosis factor-alpha inhibitorsNecrosis factor-alpha inhibitorsInterleukin-12/23 inhibitorsShort-term safetyT-cell modulatorDevelopment of biologicsBiologic therapyPsoriasis patientsPsoriatic patientsClinical trialsTherapeutic monitoringSpecific patientPatientsBiologicsMedicationsPsoriasisLong-term dataAdministrationTreatmentCurrent bodyInhibitorsEvidence
2006
Conventional systemic agents for psoriasis. A systematic review.
Strober B, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. The Journal Of Rheumatology 2006, 33: 1442-6. PMID: 16724368.Peer-Reviewed Original Research